Cue Biopharma
78 hedge funds and large institutions have $50.5M invested in Cue Biopharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 13 closing their positions.
Holders
78
Holders Change
+15
Holders Change %
+23.81%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
23
Reduced
9
Closed
13
Calls
$586K
Puts
$111K
Net Calls
+$475K
Net Calls Change
+$371K
Top Buyers
| 1 |
1
BlackRock
New York
|
$7.54M |
| 2 |
2
State Street
Boston,
Massachusetts
|
$2.38M |
| 3 |
3
Vanguard Group
Malvern,
Pennsylvania
|
$7.48M |
| 4 |
4
Geode Capital Management
Boston,
Massachusetts
|
$2.66M |
| 5 |
5
Northern Trust
Chicago,
Illinois
|
$1.21M |
